Lonza and Clovis Oncology sign long-term manufacturing agreement to secure supply of rucaparib
First dedicated small-molecule manufacturing line to be constructed in Visp, Switzerland.
Lonza has entered into a long-term commercial supply agreement with Clovis Oncology for the manufacture of Clovis’s development-stage PARP inhibitor, rucaparib. The focus of the agreement is to provide Clovis with security of supply and the flexibility to react swiftly to changes in market demand scenarios. Both companies are strengthening their relationship after a successful collaboration on clinical manufacturing of the highly potent API.
Rucaparib is a candidate targeting various cancer types through the inhibition of DNA-repair enzyme poly-ADP ribose polymerase-1, 2 and 3 (PARP-1, -2 and -3). The FDA has granted the molecule Breakthrough Therapy Designation for monotherapy treatment of patients with advanced ovarian cancer with BRCA-mutated tumours and who have been treated with two or more chemotherapies.
Under the agreement with Clovis, Lonza will construct a new production train in Visp (Switzerland) that will be exclusively dedicated to the manufacture of rucaparib. With this agreement Lonza implements a new dedicated facility concept for small molecules using modern technologies, including extensive on-line analytical monitoring that is designed to facilitate real-time release testing. The dedicated train guarantees access to manufacturing capacity for Clovis and allows coverage of the full range of anticipated demand scenarios for commercial supply.
By the beginning of 2019, the new train should be completed and operationally qualified. Until the completion of the new train, Lonza will manufacture rucaparib in its existing facilities in Visp with dedicated access to capacity. The agreement represents a comprehensive supply strategy supporting the customers ongoing business needs through commercialization and ongoing market supply.
“We’re looking forward to further developing our relationship into a long and productive partnership with Clovis to supply this innovative medicine to cancer patients across the globe,” said Gordon Bates, Senior Vice President, Business Unit Head, Chemical and Microbial Manufacturing for Lonza.
“Rucaparib is a highly potent drug, where our expertise in safely handling and scaling highly potent compounds at clinical and commercial scale supported Clovis through to submission,” he added. “This latest agreement continues to demonstrate our flexibility in developing customized supply solution for accelerated approval breakthrough designation programs to support our customers as they meet some of the greatest challenges in patient treatment.”
Related News
-
News Eli Lilly gets ready to launch five new drugs in 2023
Eli Lilly, the American pharmaceutical company (IN, USA) are gearing up for a big year ahead, with hopes to launch five new drugs and capitalise on growing obesity and Alzheimer’s disease markets. -
News Amgen buys Horizon for $27.8 billion in bold step into the rare disease market
Amgen Inc buys pharmaceutical company Horizon Therapeutics in a multibillion-dollar deal, in hopes to capitalise on it's portfolio of drugs in the highly sort after rare disease market. -
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Merck to donate new Ebola vaccine to defend against outbreaks in Uganda
Pharmaceutical giant Merck has announced they will be speeding up the processing of a new vaccine against the latest strain of the Ebola virus, to be donated to a global non-profit organisation for distribution -
News CPHI Podcast Series: Driving innovation with pharmaceutical startups
The latest episode in the CPHI Podcast Series explores how startups are driving innovation by taking high-risk approaches and doing business with greater agility. -
News Greener and efficient processes: Quaternary Ammonium Salts
Quaternary Ammonium Salts play a crucial part in Organic Chemistry processes at many major industries. Discover why.
-
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance